Spontaneous retroperitoneal hemorrhage

Am J Surg. 2005 Mar;189(3):345-7. doi: 10.1016/j.amjsurg.2004.11.020.

Abstract

Background: We evaluated patients with spontaneous retroperitoneal hemorrhage for reliable predictors of early diagnosis and improved outcomes.

Methods: A retrospective chart review was done to determine patient demographic and laboratory findings, presenting symptoms, time to diagnosis, anticoagulant and/or antiplatelet agent use, transfusions, and patient outcome.

Results: One hundred nineteen patients were identified; 14 (12%) died (mean age 77 +/- 9 years vs. 74 +/- 10 years for survivors [P = 0.235]). All nonsurvivors were on anticoagulants: 8 of 89 (9%) were on heparin or warfarin alone, and 6 of 23 (26% [P = 0.028]) were on a combined anticoagulant-antiplatelet regimen. Symptom onset to computed axial tomography (CAT) scan averaged 1.3 +/- 1.3 days for nonsurvivors versus 1.5 +/- 1.9 days for survivors (P = 0.778). Hemoglobin was 9.07 +/- 3.35 for nonsurvivors versus 9.60 +/- 2.07 for survivors (P = 0.435). Eighty-eight patients were transfused, and 10 died; 31 patients had no transfusion, and 4 of these died (P = 0.821).

Conclusions: A high index of clinical suspicion is necessary for diagnosis of spontaneous retroperitoneal hemorrhage because these patients present with a variety of symptoms. Prospective studies are necessary to determine whether earlier diagnosis combined with aggressive resuscitation can impact the high mortality rate seen in these patients.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anticoagulants / adverse effects
  • Blood Coagulation Tests
  • Blood Transfusion
  • Early Diagnosis
  • Female
  • Hemoglobins / analysis
  • Hemoperitoneum / diagnosis*
  • Hemoperitoneum / etiology*
  • Hemoperitoneum / mortality
  • Humans
  • Male
  • Middle Aged
  • Outcome Assessment, Health Care
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Count
  • Retroperitoneal Space
  • Retrospective Studies
  • Risk Factors

Substances

  • Anticoagulants
  • Hemoglobins
  • Platelet Aggregation Inhibitors